This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive
compensation for actions taken through them.
AbbVie Inc. (NYSE: ABBV) reported its third-quarter financial results before the markets opened on Friday. The company posted $1.21 in earnings per share (EPS) and $6.43 billion in revenue. The consensus estimates from Thomson Reuters had called for $1.20 in EPS on revenue of $6.56 billion. The same period of last year reportedly had EPS of $1.13 and $5.94 billion in revenue.
Global Humira sales increased 11.3% on a reported basis. Operational Humira sales increased 12.1%, excluding a 0.8% impact from foreign exchange. Humira global revenues totaled $4.06 billion.
At the same time, global Imbruvica net revenue was $501 million, with U.S. sales of $437 million and international profit sharing of $64 million for the quarter.
In terms of the outlook for the full year, the company expects EPS to be in the range of $4.80 to $4.82, compared with the consensus estimates of $4.82 in EPS and $25.85 billion in revenue for the year.
AbbVie is also announcing that its board of directors declared an increase in the company’s quarterly cash dividend to $0.64 per share from $0.57 per share, beginning with the dividend payable on February 15, 2017, to shareholders of record as of January 13, 2017.
Richard A. Gonzalez, board chair and chief executive of AbbVie, commented:
We delivered another strong quarter, with EPS growth ahead of our expectations. Year-to-date, we’ve driven strong commercial, operational and R&D execution, and we have advanced our pipeline and other strategic priorities. AbbVie represents a unique investment opportunity, offering both compelling growth, along with a strong return of capital to investors, including a rapidly growing dividend, which has grown 60 percent since we became an independent company nearly four years ago.
Shares of AbbVie traded down more than 7% to $56.79 Friday morning, with a consensus analyst price target of $71.21 and a 52-week trading range of $50.71 to $68.12.
Cash Back Credit Cards Have Never Been This Good
Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.